Treatment of Large Venous Thrombophlebitis

Primary Recommendation: LMWH as First-Line Therapy

The American College of Chest Physicians recommends LMWH (enoxaparin or dalteparin) over IV unfractionated heparin (Grade 2C) and over subcutaneous unfractionated heparin (Grade 2B) for treating acute DVT 1, 2
Enoxaparin 1 mg/kg subcutaneously twice daily or 1.5 mg/kg once daily is the clinical standard for outpatient DVT treatment, with a strength of evidence of Grade 2C 2, 3
Dalteparin 200 IU/kg subcutaneously once daily is an equivalent alternative to enoxaparin, with a strength of evidence of Grade 2B 2, 3
Once-daily dosing is preferred over twice-daily administration (Grade 2C) for LMWH 1, 4

LMWH carries a significantly lower risk of heparin-induced thrombocytopenia (HIT) compared to UFH, eliminating the need for routine platelet monitoring in most patients, with a strength of evidence of Grade 2B 2, 3
No laboratory monitoring is required for LMWH, unlike IV heparin which requires aPTT checks every 4 hours, with a strength of evidence of Grade 2C 2

IV heparin should be reserved for patients with massive PE causing hypotension (systolic BP <90 mmHg) where thrombolytic therapy is being considered or planned, with a strength of evidence of Grade 2C 4
Situations requiring immediate, titratable anticoagulation with rapid reversibility also warrant the use of IV heparin, with a strength of evidence of Grade 2B 4

For LMWH, the American College of Chest Physicians recommends enoxaparin 1 mg/kg SC twice daily OR 1.5 mg/kg SC once daily, with a strength of evidence of Grade 2C 2, 3
Dalteparin 200 IU/kg SC once daily (maximum 18,000 IU) is also recommended, with a strength of evidence of Grade 2B 2, 3
LMWH should be continued for a minimum of 5 days AND until INR ≥2.0 for at least 24 hours if transitioning to warfarin, with a strength of evidence of Grade 2C 1, 2

Renal dosing adjustments are necessary in patients with CrCl <30 mL/min, where enoxaparin should be reduced to 1 mg/kg once daily or IV UFH used instead, with a strength of evidence of Grade 2B 2, 3
Platelet monitoring is required every 2-3 days from day 4-14 when using any form of unfractionated heparin, with a strength of evidence of Grade 2C 2, 3
Warfarin initiation should not be delayed, and should be started on day 1 of heparin therapy, with a strength of evidence of Grade 2C 1, 4

The American College of Chest Physicians strongly prefers LMWH over warfarin for extended therapy in cancer patients (Grade 2B) 1
Dalteparin has demonstrated superior efficacy (4% vs 11% recurrence) in cancer patients, with a strength of evidence of Grade 2B 5
LMWH is the anticoagulant of choice throughout pregnancy, with a strength of evidence of Grade 2C 5, 3
In obese patients, weight-based dosing without capping maximum doses for LMWH is recommended, with a strength of evidence of Grade 2B 2